Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease

doi:10.3748/wjg.v23.i17.3150

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13946)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

1387

WORD

337

HTML

8332

Figures (1-4)

148

Tables (1-5)

142

Sum=10346

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1308

Download

2292

Sum=3600

May 7, 2017 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (94)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. May 7, 2017; 23(17): 3150-3162
Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3150

Table 1 Main characteristics of 46 patients recruited for the study

Parameter	Value (mean ± SD or frequency)
Population n (%)
Total	46
M	29 (63%)
F	17 (37%)
Age (yr)
Range	26-71
mean ± SD	47.5 ± 12
BMI (kg/m²)
Range	18.9-45.3
mean ± SD	29.3 ± 6.1
BMI (kg/m²)
Obesity grade
18.5-24.9 (normal weight)	23.90%
25-29.9 (overweight)	43.50%
30-34.9 (class I obesity)	17.40%
35-39.9 (class II obesity)	8.70%
≥ 40 (class III obesity)	6.50%
Waist circumference (cm)
M	100.88 ± 12.97
F	101.88 ± 15.07
Obesity central (Waist circumference)
M (> 10² cm)	48.30%
F (> 88 cm)	82.40%
Waist-to-hip ratio
Android obesity
M (≥ 1)	41.40%
F (≥ 0.85)	70.60%
Gynoid obesity
M (≤ 0.94)	20.70%
F (≤ 0.78)	0.00%
Components of MS²
0	4 (8.7%)
1	20 (43.5%)
2	10 (21.7%)
3	5 (10.9%)
4	5 (10.9%)
5	2 (4.3%)
Liver steatosis grade
1	3 (6.5%)
2	19 (41.3%)
3	24 (52.2%)
MedDiet Score
Range	21-41
mean ± SD	28.4 ± 3.9
Physical activity
No	24 (52.2%)
Yes	22 (47.8%)
Times¹/wk
1	6 (13%)
2	7 (15.2%)
3	7 (15.2%)
> 3	2 (4.3%)
Smoking
No	35 (76.1%)
Ex	3 (6.5%)
Yes	8 (17.4%)

¹At least 30 min of moderate/intense activity;

²According to Alberti et al[39].

Table 2 Frequency of metabolic syndrome’ components in patients with metabolic syndrome

Component	Hypertension	Blood pressure	TG	HDL	Serum glucose
n	12	6	12	7	8

TG: Triglycerides; HDL: High-density lipoprotein.

Table 3 Anthropometric, clinical and metabolic parameters at baseline, mid-intervention (3M) and end-intervention (6M) and results of the statistical analysis

Parameter	mean ± SD, BL	mean ± SD, 3M	mean ± SD, 6M	P value
Parameter	mean ± SD, BL	mean ± SD, 3M	mean ± SD, 6M	BL vs 3M	3M vs 6M	BL vs 6M
BMI (kg/m²)	29.3 ± 6.11	28.0 ± 6.21	27.5 ± 6.21	< 0.01^a	< 0.01^a	< 0.01^a
Waist circumference (cm)	101.25 ± 13.63	97.50 ± 14.07	96.24 ± 13.64	< 0.01^a	< 0.01^a	< 0.01^a
Hip-to-waist ratio	0.95 ± 0.08	0.94 ± 0.07	0.93 ± 0.08	< 0.01^a	< 0.01^a	< 0.01^a
AST (U/L)	36.16 ± 21.11	28.73 ± 11.28	24.84 ± 10.70	< 0.01^a	< 0.01^a	< 0.01^a
ALT (U/L)	65.66 ± 31.92	48.37 ± 33.44	37.33 ± 19.53	< 0.01^a	< 0.01^a	< 0.01^a
GGT (U/L)	60.19 ± 61.43	41.35 ± 36.49	39.73 ± 35.36	< 0.01^a	0.545	< 0.01^a
FA (U/L)	81.48 ± 37.19	79.54 ± 32.04	80.04 ± 35.02	0.489	0.787	0.574
Total cholesterol (mg/dL)	215.24 ± 40.78	205.04 ± 41.75	207.18 ± 38.48	0.044^a	0.598	0.097
LDL cholesterol (mg/dL)	137.70 ± 32.87	131.25 ± 35.88	130.16 ± 32.65	0.071	0.941	0.050^a
HDL cholesterol (mg/dL)	49.72 ± 10.59	50.17 ± 11.64	53.09 ± 11.86	0.550	< 0.01^a	< 0.01^a
TG (mg/dL)	133.39 ± 67.77	123.65 ± 71.31	118.24 ± 65.14	0.112	0.358	0.017^a
Serum glucose (mg/dL)	98.33 ± 15.87	94.52 ± 13.07	95.76 ± 13.46	< 0.01^a	0.133	< 0.01^a
Chol Tot/HDL	4.50 ± 1.27	4.23 ± 1.07	3.95 ± 1.15	0.013^a	0.010^a	< 0.01^a
LDL/HDL	2.89 ± 0.95	2.67 ± 0.93	2.56 ± 0.84	0.028^a	0.015^a	< 0.01^a
TG/HDL	2.87 ± 1.76	2.66 ± 1.89	2.39 ± 1.66	0.152	0.037^a	< 0.01^a
AIP	0.03 ± 0.25	-0.01 ± 0.23	-0.06 ± 0.25	0.097	0.089	< 0.01^a
HOMA- IR (mU/L)	3.25 ± 1.96	2.96 ± 1.73	2.94 ± 1.67	< 0.01^a	0.841	< 0.01^a
QUICKI	0.33 ± 0.04	0.34 ± 0.04	0.34 ± 0.03	< 0.01^a	0.330	< 0.017^a
PLR	115.37 ± 46.60	109.89 ± 51.77	113.65 ± 43.77	0.195	0.281	0.816
NLR	1.98 ± 1.12	1.88 ± 1.10	1.79 ± 0.89	0.287	0.509	0.185
FLI	61.55 ± 26.76	50.54 ± 29.37	48.83 ± 31.01	< 0.01^a	0.286	< 0.01^a
Kotronen index (%)	6.05 ± 5.02	4.10 ± 2.22	3.92 ± 2.40	< 0.01^a	0.277	< 0.01^a
VAI	1.85 ± 1.17	1.55 ± 0.71	1.32 ± 0.65	0.011	0.010	< 0.01^a
NAFLD Liver Fat Score	0.12 ± 1.63	-0.02 ± 1.42	-0.70 ± 1.20	0.418	< 0.01^a	< 0.01^a
LAP (male)	48.41 ± 28.14	37.01 ± 19.95	33.18 ± 17.49	< 0.01^a	0.166	< 0.01^a
LAP (female)	84.15 ± 63.06	78.92 ± 70.51	74.13 ± 58.89	0.290	0.452	< 0.01^a
BARD	1.09 ± 1.26	1.46 ± 1.17	1.37 ± 1.04	0.011^a	0.486	0.091
NAFLD	-2.29 ± 0.93	-2.13 ± 1.01	-2.28 ± 1.00	0.015^a	0.032^a	0.986

Values are expressed as mean ± SD.

^aP ≤ 0.05, significant difference. BL: Baseline; NAFLD: Non-alcoholic fatty liver disease; TG: Triglycerides; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase.

Table 4 Correlation between steatosis grade and anthropometric, clinical and metabolic parameters considered in this study at baseline and at end-treatment

Parameter		Grade 0 (n = 9)	Grade I (n = 15)	Grade 2 (n = 18)	Grade 3 (n = 4)	P value
Parameter		mean ± STD	mean ± STD	mean ± STD	mean ± STD	P value
BMI (kg/m²)	BL	-	30.19 ± 2.15	28.05 ± 6.47	30.11 ± 6.14	0.499
BMI (kg/m²)	6M	23.39 ± 3.52	25.94 ± 5.60	31.36 ± 6.53	25.77 ± 1.14	0.013^a
Waist circumference (cm)	BL	-	103.00 ± 1.73	96.05 ± 12.94	105.15 ± 13.91	0.122
Waist circumference (cm)	6M	86.44 ± 11.98	90.73 ± 9.24	106.03 ± 12.64	94.88 ± 9.37	< 0.01^a
Hip-to-waist ratio (-)	BL	-	0.94 ± 0.05	0.91 ± 0.08	0.98 ± 0.07	0.020^a
Hip-to-waist ratio (-)	6M	0.88 ± 0.06	0.91 ± 0.06	0.97 ± 0.08	0.93 ± 0.09	< 0.01^a
Tot Chol (mg/dL)	BL	-	260.67 ± 27.21	210.95 ± 31.20	212.96 ± 46.24	0.266
Tot Chol (mg/dL)	6M	215.89 ± 39.78	196.27 ± 62.92	212.06 ± 34.35	154.75 ± 44.90	0.078
HDL (mg/dL)	BL	-	47.00 ± 3.46	52.05 ± 13.39	48.21 ± 8.39	0.532
HDL (mg/dL)	6M	142.16 ± 33.53	130.60 ± 22.94	131.33 ± 35.27	96.25 ± 38.88	0.070
LDL (mg/dL)	BL	-	186.67 ± 37.63	133.52 ± 19.00	134.88 ± 37.05	0.119
LDL (mg/dL)	6M	54.33 ± 12.97	53.73 ± 14.08	53.56 ± 10.74	45.75 ± 1.89	0.399
TG (mg/dL)	BL	-	134.00 ± 43.28	125.21 ± 42.18	139.79 ± 85.63	0.597
TG (mg/dL)	6M	100.22 ± 31.69	119.20 ± 40.40	138.22 ± 88.51	65.25 ± 42.94	0.807
AST	BL	-	0.72 ± 0.28	0.87 ± 0.33	0.95 ± 0.67	0.435
AST	6M	0.55 ± 0.15	0.63 ± 0.19	0.67 ± 0.37	0.53 ± 0.17	0.641
ALT	BL	-	0.91 ± 0.20	1.32 ± 0.68	1.35 ± 0.64	0.419
ALT	6M	0.56 ± 0.14	0.79 ± 0.37	0.82 ± 0.50	0.67 ± 0.23	0.334
AST/ALT	BL	-	0.76 ± 0.15	0.71 ± 0.19	0.66 ± 0.20	0.276
AST/ALT	6M	0.95 ± 0.15	0.76 ± 0.22	0.73 ± 0.26	0.78 ± 0.11	0.058
GGT	BL	-	58.67 ± 64.53	51.89 ± 54.69	42.21 ± 25.60	0.392
GGT	6M	17.00 ± 4.12	43.53 ± 25.67	44.39 ± 0.10	27.25 ± 0.50	0.147
Blood gluc. (mg/dL)	BL	-	96.67 ± 9.29	94.16 ± 15.71	101.83 ± 16.26	0.181
Blood gluc. (mg/dL)	6M	88.00 ± 1.94	91.27 ± 7.33	104.33 ± 17.03	91.50 ± 8.19	0.018^a
SM (n)	BL	-	2.67 ± 1.15	1.32 ± 1.00	2.17 ± 1.43	0.350
SM (n)	6M	1.44 ± 1.13	1.73 ± 1.28	2.28 ± 1.49	1.25 ± 0.50	0.415
Tot-Chol/HDL	BL	-	5.60 ± 1.03	4.29 ± 1.27	4.53 ± 1.26	0.637
Tot-Chol/HDL	6M	4.07 ± 0.84	3.84 ± 1.55	4.09 ± 0.94	3.41 ± 1.09	0.479
LDL/HDL	BL	-	4.03 ± 1.14	2.72 ± 0.82	2.88 ± 0.96	0.355
LDL/HDL	6M	2.70 ± 0.82	2.60 ± 0.90	2.54 ± 0.82	2.12 ± 0.91	0.333
TG/HDL	BL	-	2.83 ± 0.78	2.63 ± 1.36	3.07 ± 2.11	0.516
TG/HDL	6M	1.92 ± 0.73	2.44 ± 1.25	2.79 ± 2.24	1.46 ± 1.02	0.698
AIP	BL	-	0.44 ± 0.11	0.37 ± 0.21	0.39 ± 0.29	0.983
AIP	6M	0.25 ± 0.19	0.34 ± 0.21	0.35 ± 0.27	0.08 ± 0.31	0.780
HOMA-IR (mU/L)	BL	-	2.77 ± 0.22	2.37 ± 1.37	4.01 ± 2.18	0.015^a
HOMA-IR (mU/L)	6M	1.50 ± 0.84	2.47 ± 1.06	4.12 ± 1.71	2.67 ± 1.51	< 0.01^a
QUICKI	BL	-	0.33 ± 0.00	0.35 ± 0.04	0.32 ± 0.03	0.082
QUICKI	6M	0.37 ± 0.05	0.34 ± 0.02	0.32 ± 0.02	0.34 ± 0.03	< 0.01^a
PLR	BL	-	120.89 ± 28.83	107.31 ± 32.51	121.06 ± 57.08	0.467
PLR	6M	93.44 ± 22.18	106.95 ± 48.08	127.33 ± 47.95	122.70 ± 30.46	0.058
NLR	BL	-	1.36 ± 0.37	1.79 ± 0.80	2.21 ± 1.34	0.112
NLR	6M	1.32 ± 0.21	1.67 ± 1.08	2.21 ± 0.85	1.44 ± 0.50	0.097
FLI	BL	-	98.97 ± 0.30	98.84 ± 0.39	98.70 ± 0.75	0.612
FLI	6M	98.48 ± 0.72	98.79 ± 0.40	98.75 ± 0.67	97.08 ± 1.82	0.143
Kotronen index (%)	BL	-	4.63 ± 2.14	4.3 ± 2.0	7.6 ± 6.4	0.047^a
Kotronen index (%)	6M	2.15 ± 0.83	3.5 ± 1.0	5.3 ± 3.2	3.1 ± 0.6	0.017^a
VAI	BL	-	3.5 ± 1.8	1.9 ± 1.0	1.6 ± 1.1	0.041^a
VAI	6M	1.44 ± 0.64	1.38 ± 0.65	1.29 ± 0.67	0.9 ± 0.67	0.224
NAFLD fat liver score	BL	-	-0.42 ± 0.9	-0.6 ± 1.1	0.7 ± 1.8	0.016^a
NAFLD fat liver score	6M	1.88 ± 0.71	-0.84 ± 0.78	0.07 ± 1.27	-0.99 ± 0.63	< 0.01^a
LAP (male)	BL	-	52.00 ± 0.00	44.27 ± 19.98	50.51 ± 32.82	0.694
LAP (male)	6M	25.67 ± 11.38	31.11 ± 14.62	42.38 ± 19.13	26.11 ± 22.32	0.386
LAP (female)	BL	-	72.10 ± 32.56	56.13 ± 31.50	130.21 ± 83.11	0.377
LAP (female)	6M	24.42 ± 16.25	52.21 ± 23.70	109.22 ± 67.63	-	0.147
BARD	BL	-	2.33 ± 1.15	0.79 ± 1.08	1.17 ± 1.34	0.733
BARD	6M	1.89 ± 0.33	1.07 ± 1.03	1.56 ± 1.15	0.50 ± 1.00	0.192
NAFLD	BL	-	-3.41 ± 0.48	-2.25 ± 0.73	-2.17 ± 1,02	0.112
NAFLD	6M	-2.44 ± 0.93	-2.68 ± 0.87	-1.88 ± 1.07	-2.27 ± 0.91	0.144
MedDiet Score	BL	-	30.0 ± 3.0	29.6 ± 4.6	27.2 ± 3.1	0.044^a
MedDiet Score	6M	NA	NA	NA	NA	NA

^aP ≤ 0.05, significant difference. NAFLD: Non-alcoholic fatty liver disease; TG: Triglycerides; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase.

Table 5 Correlation between BMI and anthropometric, clinical and metabolic parameters considered in this study at baseline and at end-treatment

Parameter		P value	Parameter		P value
Steatosis grade	BL	0.499	TG/HDL	BL	0.370
Steatosis grade	6M	0.013^a	TG/HDL	6M	0.416
Waist circumf. (cm)	BL	< 0.01^a	AIP	BL	0.194
Waist circumf. (cm)	6M	< 0.01^a	AIP	6M	0.307
Hip-to-waist ratio (-)	BL	0.231	HOMA-IR (mU/L)	BL	< 0.01^a
Hip-to-waist ratio (-)	6M	0.020^a	HOMA-IR (mU/L)	6M	< 0.01^a
Tot Chol (mg/dL)	BL	0.257	QUICKI	BL	< 0.01^a
Tot Chol (mg/dL)	6M	< 0.01^a	QUICKI	6M	< 0.01^a
HDL (mg/dL)	BL	0.255	PLR	BL	0.213
HDL (mg/dL)	6M	< 0.01^a	PLR	6M	0.645
LDL (mg/dL)	BL	0.211	NLR	BL	0.066
LDL (mg/dL)	6M	0.768	NLR	6M	0.167
TG (mg/dL)	BL	0.352	FLI	BL	< 0.01^a
TG (mg/dL)	6M	0.229	FLI	6M	0.137
AST	BL	0.244	Kotronen index (%)	BL	0.038^a
AST	6M	0.093	Kotronen index (%)	6M	< 0.01^a
ALT	BL	0.504	VAI	BL	0.479
ALT	6M	0.154	VAI	6M	0.373
AST/ALT	BL	0.195	NAFLD fat liver score	BL	< 0.01^a
AST/ALT	6M	0.114	NAFLD fat liver score	6M	< 0.01^a
GGT	BL	0.075	LAP (male)	BL	< 0.01^a
GGT	6M	0.176	LAP (male)	6M	< 0.01^a
MS (n)	BL	0.025^a	LAP (female)	BL	0.075
MS (n)	6M	0.025^a	LAP (female)	6M	0.176
Blood gluc. (mg/dL)	BL	0.182	BARD	BL	< 0.01^a
Blood gluc. (mg/dL)	6M	0.142	BARD	6M	0.079
Tot-Chol/HDL	BL	0.218	NAFLD	BL	0.058
Tot-Chol/HDL	6M	0.090	NAFLD	6M	0.167
LDL/HDL	BL	0.185	MedDiet Score	BL	0.049^a
LDL/HDL	6M	0.087	MedDiet Score	6M	NA

^aP ≤ 0.05, significant difference. TG: Triglycerides; HDL: High-density lipoprotein.

Citation: Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(17): 3150-3162
URL: https://www.wjgnet.com/1007-9327/full/v23/i17/3150.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i17.3150